SciELO - Scientific Electronic Library Online

vol.69 issue2Quality of life assessment for health promotion groupsOverweight in young adult students: the vulnerability of a distorted self-perception of body image author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista Brasileira de Enfermagem

Print version ISSN 0034-7167On-line version ISSN 1984-0446

Rev. Bras. Enferm. vol.69 no.2 Brasília Mar./Apr. 2016 


Pressure ulcer healing with Plenusdermax® Calendula officinalis L. extract

Marcelo BuzziI 

Franciele de FreitasII 

Marcos de Barros WinterIII 

IRede Sarah de Hospitais de Reabilitação. Brasília, Distrito Federal, Brazil.

IIPhytoplenus Bioativos Sociedade Anônima. Pinhais, Paraná, Brazil.

IIIHospital da Santa Casa de Misericórdia de Curitiba, Dermatology Department. Curitiba, Paraná, Brazil.



to evaluate the therapeutic benefits of the bioactive extracts of Plenusdermax®Calendula officinalis for pressure ulcer healing.


an observational cohort study, including 41 patients with a diagnosis of pressure ulcer that was stable in size for more than three months. Patients were evaluated every two weeks, over 30 weeks, for: reduction of the wound area, infection control, types of tissue and exudate, and ulcer microbiology.


the proportions of patients who were completely healed after 15 and 30 weeks of treatment were 63% and 88%, respectively, and the mean healing time was 12.5±7.8 weeks. No adverse events were observed during treatment.


the results of the study indicate that bioactive C. officinalis Plenusdermax® is a safe treatment that promotes healing of pressure ulcers.

Key words: Pressure Ulcer; Wound Healing; Inflammation; Anti-inflammatory; Calendula Officinalis


Pressure ulcers, also known as skin ulcers, decubitus ulcers and bedsores, are complex, chronic wounds. They are a frequent cause of morbidity in patients in hospitals and nursing homes, requiring expensive and time-consuming treatments(1). The healing process of chronic wounds, such as pressure ulcers, is more complex than that of acute wounds, which leads to difficulties in treatment management. Chronic wounds such as pressure ulcers might never heal if not properly treated(2). Pressure ulcers are areas of localized skin injuries and underlying tissues that usually develop over bony prominences. They occur as a result of continuous pressure on the skin, soft tissue, muscle and bone, leading to localized ischemia, followed by a cascade of processes that result in necrosis(3). The body areas commonly prone to pressure ulcers include the heels, hips, elbows, shoulders, back of the head, knees, thighs and toes(3). Ulcer severity is assessed in several ways, but the pressure ulcer staging system in the United States (United States National Pressure Ulcer Advisory Panel - NPUAP) is the most widely used across the health care community. The NPUAP system includes a four-stage classification, representing progressive severity from intact skin with non-blanchable redness of an area in Stage I, to full thickness tissue loss with exposed bone, tendon or muscle in Stage IV(2-4).

Local treatment of pressure ulcers is based on the use of dressings that protect the wound and provide a favorable environment for healing to occur. International guidelines for the treatment of pressure ulcers include essential procedures, such as: pressure relief therapy on the injured area, through consistent repositioning of the patient in bed; nutritional diet that is rich in proteins, carbohydrates, vitamins, minerals and important microelements to support formation of granulation tissue; infection control with adequate asepsis and antibiotic therapy; wound bed preparation of injury bed with debridement of necrosis and devitalized tissue; specialized dressings for the preservation of the wound bed; plastic surgery; and, use of topical therapies that are adjuvant to stimulate tissue repair(2-4).

Several topical products have been developed to reduce the healing time and pain, absorb exudate and blood, and promote rapid healing of the wound(5-6). The topical adjuvant therapies based on natural products and plants for chronic ulcers have been widely used to reduce healing time, infection, inflammation and edema(7). Calendula officinalis flower extracts are used in many topical preparations, such as anti-inflammatory agents, healing agents of skin and mucous membrane injuries, and for the treatment of herpes, solar erythemas, burns, and dermatitis(8). The treatment of pressure ulcers in hospitals and home care remains challenging for the nursing team, which motivates research for new, more effective products, despite the various adjuvant therapies currently available, such as antimicrobials, advanced dressings, prepared from natural products, growth factors, among others.

The main objective of this observational clinical cohort study was to evaluate the therapeutic benefits of the bioactive extracts of Plenusdermax®Calendula officinalis (C. officinalis) in the treatment of pressure ulcers, specifically in the processes of healing, control of microbial colonization, tissue evolution of the wounds, pain management, and also in nursing interventions such as debridement and dressing changes of patients who are bedridden at home or those who are wheelchair users.


Ethical aspects

This study was approved by the Institutional Committee of Ethics on Research at PUC-PR and was registered in Plataforma Brasil with the National Commission for Research Ethics. Informed consent was obtained from all patients before screening.

Study design, setting and period

The efficacy of Plenusdermax®C. officinalis hydroglycolic extract in the healing of pressure ulcers was clinically evaluated in a prospective, observational study over a 30-week period. The study was performed between May of 2012 and December of 2013, and the bedridden and wheelchair patients with pressure ulcers were first seen at the outpatient clinic of the Dermatology Department of Hospital da Santa Casa de Misericórdia, Curitiba, Catholic University of Paraná (PUC-PR).

Inclusion and exclusion criteria

Patients with pressure ulcers in the metropolitan area of Curitiba were selected, according to the inclusion and exclusion criteria shown in Box 1.

Box 1 Inclusion and exclusion criteria for people with pressure ulcer 

Inclusion criteria Exclusion criteria
• Age between 18 and 90 years. • Stage IV pressure ulcers or necrotic tissue that could not be adequately debrided by the nursing team.
• No previous history of allergy to any plant of the Asteraceae family • Pressure ulcers with clinical evidence of apparent infec-tion, e.g., ulcers surrounded by an advanced, hard red edge, hot or tender with very purulent exudate.
• Pressure ulcer (target ulcer) determined by clinical as-sessment, present for at least five weeks from the date of the screening visit, with a surface area between 1-30 cm2 measured by computerized planimetry, in the sacral or trochanteric region, classified as stage II to III, according to NPUAP PUSH scale. • Individuals with an infected target ulcer, including (but not limited to) cellulitis, osteomyelitis, or gangrene, infections of deeper tissues.
• Non-diabetic patients (type 1 or type 2), as diagnosed by a physician, with adequate glycemic control during selection. Blood glucose, glycosylated hemoglobin A1c, serum albumin, blood count, erythrocyte sedimen-tation rate, bacterioscopy, swab culture and antibiogram of the wound bed, measured at the screening visit, to help the researcher in selection. • Clinically significant medical conditions that can impair wound healing (e.g., kidney, liver, anemia, severe malnutrition and immunocompromising).
• Willingness to be visited by the nursing team during the study period. • Pregnant women of childbearing age who do not use an approved method of contraception.
• Individuals or caregivers who can follow strict protocol recommendations required during the study period. • Individuals who are receiving or have received corticosteroids, immunosuppressants, radiation or chemotherapy systemically (oral/intravenous) within four weeks of entering the study.
• History of Plenusdermax® use in the target ulcer less than 12 weeks before the screening visit.
• History of drug or alcohol abuse in the previous year, or those who currently use illicit drugs.
• Individuals with any other condition which, in the opinion of the investigator, would render the patient ineligible for the study.

Study protocol

The nursing team monitored the patients every two weeks for 30 weeks, or until complete healing of the ulcer occurred. Healing was confirmed one week after complete healing and was monitored for another two weeks. At baseline, a complete medical history and an assessment of the current condition of the patients were recorded. Sociodemographic data, medical history, clinical evaluation of wounds, and cleaning procedures were collected and assessed. The initial patient conditions were evaluated in terms of the duration of the ulcer, glycemic control, current activity level, nutritional status, and pain score according to the numerical pain scale(9). Patients were scored according to the Pressure Ulcer Scale for Healing (PUSH) tool (NPUAP) to estimate the severity and staging of the pressure ulcers(4). Blood tests results were included: glucose level, serum albumin, blood count and erythrocyte sedimentation rate, bacterioscopy and culture of the ulcer bed.

The microbiological flora was evaluated based on biogram/antibiogram of swab collection from the wound bed. The wounds were photographed and the area determined by computerized planimetry, using ImageJ® software (National Institutes of Health, Bethesda, MD, USA), and an area known as standard(10). The clinical appearance of the wounds was characterized according to the presence of granulation tissue, fibrin, exudate, unpleasant odor, epithelialization and necrosis.

Treatment with Plenusdermax®

The healing product based on Phytoplenus Plenusdermax® (Phytoplenus Bioativos S.A., Pinhais, PR, Brazil), with a liquid presentation and topical spray application, was used twice daily after cleaning the wound with sterile saline. The study participants, patients and their caregivers, were informed verbally and in writing, about the dosage, conditions for drug storage, as well as guidelines for use, care for and change of dressings, along with the informed consent. The spray was thoroughly applied to the wound, leaving the wound bed and wound edges moistened with the product. In the case of tunneled ulcers, the product was applied in excess to reach inside the cavity. In the case of Stage II pressure ulcers, the bubbles were not burst and Plenusdermax® was applied twice a day in the wound region, leaving the product to dry for five minutes. In Stage III pressure ulcers, the product was applied twice a day in the wound region and allowed to dry for five minutes. After application and drying of the product, the wound area was occluded with gauze and affixed with sterile micropore. As preventive measures, the incident pressure was reduced and intensive decubitus change was performed (2/2 h to 1/1h). In tunneled ulcers, no gauze was packed into the tunnels, only the orifice was occluded. Exudate control was performed by observing the amount drained, and adjustments were made with more frequent changes of sterile gauze dressings.

In all visits, photographs of the ulcers were obtained by the nursing team for the planimetry, to estimate the wound areas and to evaluate their clinical aspects. Quantitative parameters were evaluated every two weeks from the beginning until the completion of the study (30 weeks). Complete wound closure was defined as complete ulcer epithelialization without any drainage. Patients who experienced an allergic reaction to Plenusdermax®, or a substantial bacterial infection, were treated by the medical director investigator. Patients who suffered allergic reactions were removed from the clinical trial, whereas antibiotic therapy was administered in cases of infection. Patients who had fever and other infectious complications resulting from their wounds during the treatment period were excluded.

Statistical analysis

Quantitative variables (mean, median, minimum, maximum, and standard deviation) were used for descriptive statistics. The qualitative variables were described as frequencies and percentages. The wound contraction (mm2/week) per week (WoC) was calculated as the initial wound area (iWA) minus the final wound area (fWA), divided by the number of weeks:

The healing rate by week (WHR%) was calculated as follows:

The healing time was evaluated based on the calculation of the cumulative frequency plot. The Mann-Whitney's U test for matched pairs was used to evaluate the differences in the measured variables at the beginning and at the end of the treatment period. Results with a p<0.05 were considered statistically significant. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) statistical software, version 20.0 (IBM Corp. Armonk, NY).


The patient demographics and ulcer characteristics at baseline and after 30 weeks of treatment with Plenusdermax® are shown in Table 1. Of the 41 patients treated with Plenusdermax®, 14 (34%) were female and 27 (66%) were male. Patients had a mean PUSH score of 9.63±2.41, which rose to 2.24±4.21 at the end of the 30-week treatment. The neuropathic pain scale showed a mild mean pain score (1.6) due to the high number of spinal cord injury patients. The glucose, serum albumin and hemoglobin levels were normal in all patients during the study. There were no significant differences in blood parameters between patients who achieved complete wound closure within 30 weeks and those who did not (p=0.503, Student's t-test).

Table 1 Demographic characteristics of patients with pressure ulcers at the beginning and after 30 weeks of treatment 

Characteristics At the beginning After 30 weeks
Male n (%) 27 (66%)
Female n (%) 14 (34%)
Age 53 ± 12.3
Blood tests
Blood glucose (mg/dL) 95.3 ± 18.2
Serum albumin (g/dL) 4.04 ± 0.74
Hemoglobin (g/dL) 13.2 ± 1.58
Pain score (1–10) 0.8 ± 1.95(a)
PUSH Score 2.24 ± 4.21(a)
Ulcer parameters:
Classification n (%)
Stage II 2 (4.9%)(a)
Stage III 3 (7.3%)(a)
Location: n (%)
Buttocks 18 (42.8%) 6 (14.3%)(a)
Sacrum 9 (21.4%) 2 (4.8%)(a)
Trochanter 6 (14.3%) 1 (7.2%)(a)
Heel 3 (7.2%) 0 (0.0%)(a)
Back 2 (4.8%) 0 (0.0%)(a)
Thigh 2 (4.8%) 0 (0.0%)(a)
Leg 1 (2.4%) 0 (0.0%)(a)
Toes 1 (2.4%) 0 (0.0%)(a)
Duration (weeks) 41.4 ± 36.6 -
Ulcer baseline area (cm2) 3.74 ± 2.34 0.54 ± 1.66(a)
Aspect of the wound bed
% Epithelium 5.1% 87.8%(a)
% Granulation 68.4% 21.3%(a)
% Moderate exudate 78.1% 12.2%(a)
% Fibrin 26.8% 7.3%(a)
% Necrosis 12.2% 0.0%(a)
% Unpleasant odor 36.6% 2.4%(a)
Ulcer microbiology
Staphylococcus aureus 14.8% 0.0%(a)
Pseudomonas aeruginosa 7.3 % 2.4%(a)
Klebsiella pneumoniae 4.9 % 0.0%(a)
Escherichia coli 14.8% 4.8%(a)
Others 12.2% 2.4%(a)


(a)Significant difference (Mann-Whitney’s U Non-parametric Test, p <0.05); Values are mean ± standard deviation, unless otherwise stated.

Most patients had Stage III pressure ulcers (70.7%), typically in the buttocks (43%), sacral (21%) and trochanteric (14%) regions. All pressure ulcers and wounds were characterized as chronic, because the patients developed them on average 41.4±33.6 weeks before the start of the study. The mean wound area at baseline was 3.74±2.34cm2 (range: 1.1 to 11.0 cm2). The biogram/antibiogram swab tests collected from the wound beds and within the lesions showed that 43.9% (18/41) of the ulcers were clinically colonized. Staphylococcus aureus and Escherichia coli were the predominantly present pathogens (15%, 6/41 each), followed by Pseudomonas aeruginosa (7%, 3/41) and Klebsiella pneumoniae (5%, 2/41).

Healing time and reduction of wound area

The time analysis indicated a linear increase in the proportion of patients who achieved complete healing after two to 30 weeks of treatment (Figure 1). Thus, a minimum eight-week period of treatment was necessary for complete ulcer healing, the mean healing time of about 12.5±7.8 weeks. After 15 weeks of treatment, 63% of ulcers were completely healed, with notable improvements in appearance, compared to baseline. After 30 weeks, the proportion of completely healed wounds was 88%. No adverse events were observed during treatment.

Figure 1 Proportion of healed pressure ulcers during the 30-week treatment with Plenusdermax® 

Based on the fact that pressure ulcers with larger areas take longer to heal than smaller ulcers, and due to the large variation (range 1.1 to 11.0 cm2) in the initial area of the ulcers, it was necessary to separate the sample into two groups, based on the initial ulcer area in order to more accurately assess the healing rates. The first group included those with smaller ulcers ranging from 1.0 to 3.9 cm2; the second included those with larger ulcers, ranging from 4.0 to 11.0 cm2 (Table 2).

Table 2 Healing parameters of patients with pressure ulcer treated with Plenusdermax® for 30 weeks 

Groups according to ulcer size (cm2) All Smaller 1.0 – 3.9 Bigger 4.0 – 10.0 p value*
Number of patients 41 29 12
Duration (weeks) 41.4 ± 33.6 42.3 ± 36.2 39.3 ± 22.6 0.850
Initial area (cm2) 3.74 ± 2.82 2.23 ± 0.81 7.71 ± 2.65 ≤ 0.001
Final area (cm2) 0.55 ± 1.66 0.00 ± 0.00 2.03 ± 2.65 ≤ 0.001
Mean time until healing (weeks) 12.0 ± 7.85 11.7 ± 7.64 12.9 ± 9.45 0.857
% healing (30 weeks) 87.8 100.0 58.3
Wound contraction index per week (WoC - mm2/week) 36.1 ± 32.6 30.2 ± 24.3 45.8 ± 41.8 0.465
Percentage wound rate (WHR%) 12.4 ± 11.1 14.3 ± 11.7 6.6 ± 5.3 0.027


*Mann Whitney’s Non-parametric U Test, p < 0.05; Values are mean±standard deviation, unless otherwise stated.

Regarding the duration of ulcers before the study, there was no significant difference between the group of smaller ulcers and the group of larger ulcers (p=0.850, Mann-Whitney's U test) (Table 2). As predicted, the group of smaller ulcers had a mean ulcer area at baseline (2.23 cm2) that was significantly lower (p≤0.001) than the group of larger ulcers (7.71cm2). At the end of 30 weeks, all ulcers smaller than 4.0 cm2 were completely healed, whereas 58% of larger ulcers were completely healed (Table 2).

Despite the mean healing time of smaller ulcers being lower than that of larger ulcers during the 30-week period of the study, these values are not statistically different (p=0.857, Mann-Whitney's U test). Although not statistically significant (p=0.465), the wound contraction rate per week (WoC - mm2/s) was 52% higher in the larger ulcers than in the smaller ones, indicating, in absolute terms, a greater contraction ratio in the larger wounds. The percentage healing rate by week (WHR%), which considers the initial wound area in smaller ulcers (14.3%) was significantly two times faster than in the larger ulcers (6.6%). Collectively, these data suggest that the healing benefits of Plenusdermax® is not dependent on the initial size of the pressure ulcer.

Inflammation and microbiology of the pressure ulcers

After 30 weeks of treatment with Plenusdermax®, the total number of colonized pressure ulcers was significantly reduced from 18 (44%) to 5 (12.1%) (Mann-Whitney's U test; p=0.011; Table 1). It is also important to mention that Plenusdermax® was equally effective against all pathogens identified in the wounds. Therefore, the number of wounds that had an unpleasant odor at baseline (36.6%) was significantly lower after two weeks, and was reduced to 2.4% after treatment. These data are consistent with the dramatic reduction in inflammatory cells and fibrin induced by Plenusdermax®. Equally interesting is the complete disappearance of necrotic tissue after treatment. Taken together, these data demonstrate that Plenusdermax® promotes closure of chronic injury through strong antimicrobial and anti-inflammatory properties that is able to prevent tissue damage.


In this observational cohort study, the beneficial effects of the bioactive Plenusdermax®C. officinalis spray was tested in healing pressure ulcers in bedridden patients and wheelchair users who used the product regularly at home, with instructions by the nursing team which is a reality in most treatments.

The treatment administered to patients followed international guidelines, including repositioning and control of tissue overload, colonization and infection control of ulcers as well as cleaning procedures and care as adjunctive therapy, i.e., Plenusdermax®. However, evidence indicates that in Brazil, the international guidelines for the treatment of pressure ulcers are not regularly followed. An observational study in a general hospital found a low level of adherence to the use of guidelines for the treatment of pressure ulcers, and, in the case of Stage II ulcers, nursing interventions consisted predominantly of cleansing with saline (57%), using vegetable oils (40%) and decubitus change maneuvers, whereas in Stage III ulcers, cleaning interventions with saline (84%) and soapy water (19%), use of debridants such as papain (32 %) and collagenase (14%), and use of antimicrobials, such as silver sulfadiazine (10%) predominated(11). Another observational cohort study showed that bedridden patients with pressure ulcers treated at home had a high risk of aggravating the healing process, had an overall worse condition which resulted in a three times higher morbidity when compared to other types of injuries(11). The same study also showed that domiciled patients with increased risk of developing pressure ulcers were those that had limited repositioning capability, did not feel the need to reposition, had fecal incontinence, dementia and/or difficulty feeding themselves(12).

The results obtained with the use of the bioactive extract Plenusdermax® as an adjuvant topical therapy demonstrated that, despite the adversity of home treatment, the ulcer treatment protocol is limited. Eighty-eight percent of patients who had stable ulcers for more than three months achieved complete healing over the 30-week period of the study; the mean healing time was approximately 12 weeks. A percentage of 58% of patients had more difficulty achieving complete healing, probably because they had larger ulcers, some with areas up to 11cm2. Nevertheless, the mean time to healing in these patients was not statistically different from those with smaller ulcers.

The proportion of patients who achieved complete healing with this treatment during the study period corroborated effective treatments for pressure ulcers, since studies showed that high rates of Stage III ulcer healing can reach 59% at 24 weeks, with treatment of up to one year being necessary in some patients(13).

A significant reduction in odor, edema, erythema and bacterial count was observed in the studied patients. This reduction is due to the anti-inflammatory and antibacterial properties of the bioactive extract of Plenusdermax®C. officinalis, since bacterioscopy swabs collected from the wound bed showed significant reduction of colonization by Staphylococcus aureus and Escherichia coli after using Plenusdermax®. Calendula officinalis extracts have proven to have bactericidal and fungicidal effects against pathogenic microorganisms isolated from hospital patients(14). The formation of bacterial biofilms in the wound bed of the lesions is extremely harmful to the tissue and a major contributor to the establishment of a chronic and degrading condition of the ulcers. This situation is further aggravated by the emergence of multidrug-resistant bacteria in response to the abuse of antibiotics, intensifying the search for new strategies to combat bacterial colonization(15). In many pressure ulcer healing therapies, aggressive oxidizing antiseptics are still used very frequently, such as hydrogen peroxide, hypochlorite, acetic acid, chlorhexidine, povidone/iodine, cetrimide, among others, which have antibacterial properties, but are very toxic to healthy granulation tissue(2).

The use of natural extracts for the treatment of chronic skin injuries has always been an alternative adjuvant therapy in the healing area. With the advent of recent and better technologies for obtaining natural bioactives, new therapies have contributed to tissue repair in chronic injuries, preparing the wound bed for better healing(16-18).

Plenusdermax® extract showed an increase in anti-inflammatory, anti-edematous, anti-erythematous and healing activities that corroborate previous clinical and experimental studies using C. officinalis phyto-preparations(19-24). The beneficial effects of Plenusdermax® in healing of pressure ulcers are due to bioactive constituents such as triterpenoids monoesters, triterpene alcohols, triterpenic oligoglycosides and flavonoids, which may work synergistically to promote wound healing.

The therapy using the bioactive Plenusdermax®C. officinalis spray offered advantages when compared to other adjuvant therapies for the treatment of chronic injuries. The bioactive C. officinalis extract is an aqueous preparation that leaves no solid residue adhering to the wound bed, has ease of application, facilitates the cleaning process and dressing changes, and helps the debridement process. Therefore, it minimizes friction and prevents small traumas on the emerging granulation tissue.

Although the present study is an uncontrolled observational cohort, which has limitations in determining the guaranteed clinical efficacy of randomized controlled clinical trials, the results showed that the use of the bioactive Plenusdermax®C. officinalis spray was a powerful adjuvant in the treatment of pressure ulcers, as it aids nursing interventions such as dressing changes and care of ulcers. Accordingly, the use of the spray helps clean the wound bed, aids in debridement and stimulation of granulation tissue growth, providing a better healing.


The results of this study indicate that the bioactive extract of Plenusdermax®C. officinalis is a safe and promising therapy for the treatment of pressure ulcers in bedridden and wheelchair users treated at home. The use of Plenusdermax® spray as an adjunctive topical therapy resulted in complete healing of pressure ulcers in 88% of patients during the 30-week period, in addition to helping with wound debridement, dressing change and promotion of significant reduction in bacterial colonization. However, randomized controlled trials on a larger scale with a longer follow-up are required to demonstrate clinical efficacy, to establish optimal treatment guidelines using Plenusdermax®, and also to allow for these results to be validated in a broad population.


1 Cooper L, Vellodi C, Stansby G, Avital L. The prevention and management of pressure ulcers: summary of updated NICE guidance. J. Wound Care [Internet]. 2015[cited 2014 Feb 09];24(4):179-81. Available from: ]

2 Whitney J, Phillips L, Aslam R, Barbul A, Gottrup F, Gould L, et al. Guidelines for the treatment of pressure ulcers. Wound Repair Regen [Internet]. 2006[cited 2014 Feb 09];14:663-79. Available from: ]

3 National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and treatment of pressure ulcers: quick reference guide. Emily Haesler (Ed.). Cambridge Media: Osborne Park, Western Australia; 2014. [ Links ]

4 Santos V, Azevedo M, Silva T, Carvalho V, Carvalho V. [Crosscultural adaptation of the pressure ulcer scale for healing to the portuguese language]. Rev Latino-Am Enfermagem [Internet]. 2005[cited 2014 Feb 09];13(3):305-13. Available from: Portuguese. [ Links ]

5 Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA. Treatment of pressure ulcers: a systematic review. JAMA [Internet]. 2008[cited 2014 Feb 09];300(22):2647-62. Available from: ]

6 Banks V. Pressure sores: topical treatment and the healing process. J Wound Care. 1998 May;7(5):265-6. [ Links ]

7 Avijgan M. Phytotherapy: an alternative treatment for non-healing ulcers. J Wound Care [Internet]. 2004[cited 2014 Feb 09];13(4):157-8. Available from: ]

8 Arora D, Rani A, Sharma A. A review on phytochemistry and ethnopharmacological aspects of genus Calendula. Pharmacogn Rev [Internet]. 2013[cited 2014 Feb 09];7(14):179-87. Available from: ]

9 Hawker GA, Mian S, Kendzerska T, Franch M. Measures of adult pain. Arthritis Care Res [Internet]. 2011[cited 2014 Feb 09];63(s11):s240-52. Available from: ]

10 Caetano KS, Frade MAC, Minatel DG, Santana LA, Enwemeka CS. Phototherapy improves healing of chronic venous ulcers. Photomed Laser Surg [Internet]. 2009[cited 2014 Feb 09];27(1):111-8. Available from: ]

11 Rangel EML, CaliriI MHL. Uso das diretrizes para tratamento da úlcera por pressão por enfermeiros de um hospital geral. Rev Eletr Enf [Internet]. 2009[cited 2014 Feb 09];11(1):70-7. Available from: ]

12 Smith DM. Pressure ulcers in the nursing home. Ann Inter Med [Internet]. 1995[cited 2014 Feb 09];123(6):433-8. Available from: ]

13 Thomas DR. Prevention and treatment of pressure ulcers: what works? what doesn't? Cleve Clin J Med [Internet]. 2001[cited 2014 Feb 09];68(8):704-7. Available from: ]

14 Efstratiou E, Hussain AI, Nigam PS, Moore JE, Ayub MA, Rao JR. Antimicrobial activity of Calendula officinalis petal extracts against fungi, as well as Gram-negative and Gram-positive clinical pathogens. Complement Ther Clin Pract [Internet]. 2012[cited 2014 Mar 14];18(3):173-6. Available from: ]

15 Ammons M. Anti-biofilm strategies and the need for innovations in wound care. Recent Pat Antiinfect Drug Discov [Internet]. 2010[cited 2014 Feb 09];5(1):10-7. Available from: ]

16 Dorai A. Wound care with traditional, complementary and alternative medicine. Indian J Plast Surg [Internet]. 2012[cited 2014 Feb 09];45(2):418-24. Available from: [ Links ]

17 Preethi KC, Kuttan R. Wound healing activity of flower extract of Calendula officinalis. J Basic Clin Physiol Pharmacol [Internet]. 2009[cited 2014 Feb 09];20:73-9. Available from: ]

18 Hamburger M, Adler S, Baumann D, Förg A, Weinreich B. Preparative purification of the major anti-inflammatory triterpenoid esters from Marigold (Calendula officinalis). Fitoterapia [Internet]. 2003 Jun [cited 2014 Feb 09];74(4):328-38. Available from: ]

19 Della Loggia R, Tubaro A, Sosa S, Becker H, Saar S, Isaac O. The Role of Triterpenoids in the Topical Anti-Inflammatory Activity of Calendula officinalis Flowers. Planta Med [Internet]. 1994[cited 2014 Feb 09];60(6):516-20. Available from: ]

20 Zitterl-Eglseer K, Sosa S, Jurenitsch J, Schubert-Zsilavecz M, Della Loggia R, Tubaro A, et al. Anti-oedematous activities of the main triterpendiol esters of marigold (Calendula officinalis L.). J Ethnopharmacol [Internet]. 1997[cited 2014 Feb 09];57(2):139-44. Available from: ]

21 Babaee N, Moslemi D, Khalilpour M, Vejdani F, Moghadamnia Y, Bijani A, et al. Antioxidant capacity of Calendula officinalis flowers extract and prevention of radiation induced oropharyngeal mucositis in patients with head and neck cancers: a randomized controlled clinical study. Daru [Internet]. 2013[cited 2014 Feb 09];21(1):18. Available from: ]

22 Duran V, Matic M, Jovanovć M, Mimica N, Gajinov Z, Poljacki M, et al. Results of the clinical examination of an ointment with marigold (Calendula officinalis) extract in the treatment of venous leg ulcers. Int J Tissue React [Internet]. 2005[cited 2014 Feb 09];27(3)(March):101-6. Available from: ]

23 Lavagna SM, Secci D, Chimenti P, Bonsignore L, Ottaviani a, Bizzarri B. Efficacy of Hypericum and Calendula oils in the epithelial reconstruction of surgical wounds in childbirth with caesarean section. Farmaco [Internet]. 2001[cited 2014 Feb 09];56(5-7):451-3. Available from: ]

24 Parente LML, Lino Júnior RDS, Tresvenzol LMF, Vinaud MC, de Paula JR, Paulo NM. Wound healing and anti-inflammatory effect in animal models of Calendula officinalis L. growing in Brazil. Evid Based Complement Alternat Med [Internet]. 2012[cited 2014 Jan 26];2012 ID375671;7 pgs. Available from: ]

Received: January 11, 2015; Accepted: September 29, 2015

CORRESPONDING AUTHOR: Marcelo Buzzi. E-mail:

Creative Commons License Este é um artigo publicado em acesso aberto (Open Access) sob a licença Creative Commons Attribution, que permite uso, distribuição e reprodução em qualquer meio, sem restrições desde que o trabalho original seja corretamente citado.